"Eosinophilic pneumonia"

Mepolizumab (Nucala) - for the treatment of chronic eosinophilic pneumonia Prepared by the All Wales Therapeutics and Toxicology Centre Page 1 of 4 Mepolizumab (Nucala®▼) for the treatment of chronic eosinophilic pneumonia (OW15) May 2022 ONE WALES INTERIM DECISION Mepolizumab (Nucala®▼) for the treatment of chronic eosinophilic pneumonia Date of original advice: November 2019 Date of review: May 2022 The following One Wales Medicines Assessment Group (OWMAG) recommendation has been endorsed by health board Chief Executives. It is the view of the One Wales Medicines Advisory Group (OWMAG) that mepolizumab (Nucala®) should continue to not be supported within NHS Wales for the treatment of chronic eosinophilic pneumonia. Individual Patient Funding Request (IPFR) consideration

Mepolizumab (Nucala) - for the treatment of chronic eosinophilic pneumonia Home - All Wales Therapeutics and Toxicology CentreSkip to main contentOpens in new window * NHS Wales * NHS 111 Wales * Skip Navigation * Accessibility * Contact us * CymraegCymraeg * Welcome to All Wales Therapeutics and Toxicology Centre * All...SearchAll Wales Therapeutics and Toxicology

Monoclonal antibodies in idiopathic chronic eosinophilic pneumonia: a scoping review. Idiopathic chronic eosinophilic pneumonia (ICEP) is a rare disease characterized by pulmonary radiological alterations, peripheral eosinophilia, and demonstrated pulmonary eosinophilia. Oral steroids (OSs) are the standard management, but relapses occur in up to 50% of patients during the decrease or suspension

The long-term outcomes of mepolizumab treatment at 100 mg dose on idiopathic chronic eosinophilic pneumonia: A real-life experience. The standard therapeutic regimen for idiopathic chronic eosinophilic pneumonia (ICEP) involves the administration of oral corticosteroids (OCS). However, a notable proportion of individuals experience recurrent episodes after the tapering or cessation of OCS during

Long-term use of mepolizumab in a case of chronic eosinophilic pneumonia: extending interval dosing. Mepolizumab, a humanized anti IL-5 monoclonal antibody, has been used off-label for chronic eosinophilic pneumonia (CEP), inducing disease remission and saving systemic corticosteroids. We present a case of CEP, requiring long-term corticosteroids therapy due to relapse upon withdrawal . Mepolizumab was started and maintained for 2 years and 6 months. Corticosteroids could be withdrawn and mepolizumab dose interval was spared up to 10 weeks with no disease relapse. Mepolizumab is shown to be useful for chronic eosinophilic pneumonia, allowing corticosteroid withdrawal. Dose interval may be individualized under close monitoring, for a more efficient treatment, reducing medical costs while

Daptomycin Exposure as a Risk Factor for Daptomycin-Induced Eosinophilic Pneumonia and Muscular Toxicity.

A rare case of acute eosinophilic pneumonia induced by vaping-associated lung injury: a case report. Acute eosinophilic pneumonia (AEP) is well-known as one of the primary eosinophilic pulmonary diseases of unknown etiology. It's defined as a febrile illness along with acute onset respiratory failure that is commonly misdiagnosed at the initial presentation as infectious pneumonia. Despite

Tryptase and IL-33 in Bronchoalveolar Lavage Fluid May Predict the Types of Eosinophilic Pneumonia and Disease Recurrence. Eosinophilic pneumonia (EP) is characterized by a marked accumulation of eosinophils in the lungs and blood. Eosinophils and mast cells play an important role in the pathogenesis of EP via release of biomarkers such as tryptase and interleukin (IL)-33. However, the potential

Idiopathic Chronic Eosinophilic Pneumonia Evolving to Pulmonary Fibrosis: A Retrospective Analysis. Patients with idiopathic chronic eosinophilic pneumonia (ICEP) may have pulmonary fibrosis. To investigate the predictors of pulmonary fibrosis in ICEP, to describe the timeline of pulmonary fibrosis after ICEP diagnosis, and to detail the radiologic pattern of fibrosis. A retrospective computer

Challenges in managing a multifactorial eosinophilic pneumonia: daptomycin vs strongyloidiasis case report. Eosinophilia is defined as a blood eosinophil count > 500/mcL with etiology usually an allergic reaction or parasitic infection which can lead to serious organ damage. A patient being treated for hardware infection develops eosinophilia while on daptomycin in the setting of a positive

Association between peripheral blood/bronchoalveolar lavage eosinophilia and significant oxygen requirements in patients with acute eosinophilic pneumonia. We investigated the association between a combination of two markers, peripheral (PEC) and bronchoalveolar lavage (BAL) eosinophil percentage (BEP), and oxygen requirements in patients with acute eosinophilic pneumonia (AEP). We

Ustekinumab associated chronic eosinophilic pneumonia. Ustekinumab-induced eosinophilic pneumonia is rare and to our knowledge, this is the fifth reported case of such an entity. A 60-year-old female was admitted with worsening shortness of breath and a nonproductive cough for 4 months. Her past medical history was significant for Crohn's disease and psoriatic arthritis that was previously managed with adalimumab and switched to ustekinumab 2 months before symptoms. Initial diagnostic workup showed 10% peripheral eosinophilia and a CT chest showed numerous 5 mm nodules scattered throughout the lungs along with some peripheral reticulations. Her BAL fluid analysis showed abnormally high eosinophil count (67%), greatly limiting her potential diagnoses to eosinophilic pneumonia, EGPA

Age distribution and seasonality in acute eosinophilic pneumonia: analysis using a national inpatient database. Acute eosinophilic pneumonia (AEP) is a rare inflammatory lung disease. Previous studies have shown that most patients with AEP are aged 20 to 40 years, whereas several case studies have included older patients with AEP. These studies also suggested that AEP is more prevalent in summer

Diagnostic pitfalls of acute eosinophilic pneumonia in an adolescent boy following cigarette smoking: A case report. Acute eosinophilic pneumonia (AEP) is characterized by acute febrile respiratory symptoms, bilateral lung infiltrates, and pulmonary eosinophilia. AEP is closely related to cigarette smoking but is rarely suspected in pediatric cases despite the fact that there is a relatively

Idiopathic acute eosinophilic pneumonia: A rare cause of hypoxic respiratory failure. Idiopathic Acute Eosinophilic Pneumonia (IAEP) is a life-threatening cause of hypoxic respiratory failure. IAEP is challenging to diagnose as it may mimic infectious pneumonia or acute respiratory distress syndrome. Distinguishing IAEP from these alternatives is important; the mainstay of treatment for IAEP

Elevated Periostin Concentrations in the Bronchoalveolar Lavage Fluid of Patients with Eosinophilic Pneumonia. Eosinophilic pneumonia (EP) is characterized by massive pulmonary infiltration by eosinophils. Although serum periostin is a novel marker for eosinophil-dominant asthma, the upregulation of periostin in the airway of asthmatics is controversial. In this study, we examined whether periostin concentrations are elevated in the bronchoalveolar lavage fluid (BALF) of patients with EP. BAL was performed in healthy volunteers and in patients with acute eosinophilic pneumonia (AEP), chronic eosinophilic pneumonia (CEP), and sarcoidosis. The periostin concentrations in the BALF were measured. The periostin concentration in the BALF increased significantly with pulmonary eosinophil ia

Chronic eosinophilic pneumonia after trastuzumab and radiation therapy for breast cancer: A case report. Chronic eosinophilic pneumonia (CEP) is rare and an idiopathic disorder. The disease has been associated with drugs, infection, or irradiation, and its relationship with asthma remains unclear. We reported a case of a 49-year-old female patient after trastuzumab and radiation therapy

Cigarette smoking-induced acute eosinophilic pneumonia: A case report. Acute eosinophilic pneumonia (AEP) is a rare pulmonary disease, which is characterized by diffuse pulmonary eosinophilia. The pathogenesis remains unknown. Here we report a patient with AEP following a recently acquired habit of smoking. A 21-year-old female presented with fever, dry cough, and acute hypoxic respiratory

Acute eosinophilic pneumonia in the deployed military setting. Acute eosinophilic pneumonia (AEP) is a rare but important cause of severe respiratory failure most typically caused by cigarette smoking, but can also be caused by medications, illicit drugs, infections and environmental exposures. There is growing evidence that disease severity varies and not all patients require mechanical

Favorable response to asthma-dosed subcutaneous mepolizumab in eosinophilic pneumonia.